ICON to Acquire PRA Health Sciences
ICON PLC has agreed to acquire PRA Health Sciences Inc. PRAH, 18.41% in a cash and stock deal valued at about $12 billion. Under the terms of the deal. Icon will pay $80 per share in cash plus 0.4125 shares of Icon stock for a roughly 30% premium over PRA's closing price Tuesday.
The deal is expected to close in the third quarter. The combined company will be headquartered in Dublin and continue to be led by CEO Steve Cutler, and CFO Brendan Brennan.
For more information, click
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025